GUSB

glucuronidase beta, the group of Glycoside hydrolases

Basic information

Region (hg38): 7:65960684-65982215

Links

ENSG00000169919NCBI:2990OMIM:611499HGNC:4696Uniprot:P08236AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • mucopolysaccharidosis type 7 (Definitive), mode of inheritance: AR
  • mucopolysaccharidosis type 7 (Strong), mode of inheritance: AR
  • mucopolysaccharidosis type 7 (Supportive), mode of inheritance: AR
  • mucopolysaccharidosis type 7 (Definitive), mode of inheritance: AR
  • mucopolysaccharidosis type 7 (Strong), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Mucopolysaccharidosis type VIIARBiochemicalEnzyme replacement therapy is available, and has been approved for both pediatric and adult patients; BMT has been describedBiochemical; Cardiovascular; Craniofacial; Gastrointestinal; Musculoskeletal; Neurologic; Ophthalmologic4265197; 144057; 101485; 6813001; 1702266; 7680524; 9099834; 9543069; 12403825; 12522561; 12748853; 19224584; 26908836; 28595941; 29478819
The condition can include cardiac manifestations

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the GUSB gene.

  • Mucopolysaccharidosis type 7 (39 variants)
  • not provided (4 variants)
  • Mucopolysaccharidosis type 6 (2 variants)
  • GUSB-related disorder (1 variants)
  • Inborn genetic diseases (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the GUSB gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
1
clinvar
1
clinvar
197
clinvar
9
clinvar
208
missense
2
clinvar
12
clinvar
154
clinvar
3
clinvar
1
clinvar
172
nonsense
17
clinvar
1
clinvar
1
clinvar
19
start loss
1
clinvar
1
clinvar
2
frameshift
21
clinvar
2
clinvar
2
clinvar
25
inframe indel
3
clinvar
1
clinvar
4
splice donor/acceptor (+/-2bp)
1
clinvar
7
clinvar
1
clinvar
9
splice region
11
21
2
34
non coding
1
clinvar
10
clinvar
104
clinvar
9
clinvar
124
Total 42 25 172 305 19

Highest pathogenic variant AF is 0.0000657

Variants in GUSB

This is a list of pathogenic ClinVar variants found in the GUSB region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
7-65960689-A-C Mucopolysaccharidosis type 7 Uncertain significance (Jan 12, 2018)909597
7-65960689-A-G Mucopolysaccharidosis type 7 Uncertain significance (Jan 13, 2018)360547
7-65960725-T-C Mucopolysaccharidosis type 7 Benign (Jan 12, 2018)910523
7-65960743-C-T Mucopolysaccharidosis type 7 Uncertain significance (Jan 12, 2018)910524
7-65960749-T-C Mucopolysaccharidosis type 7 Uncertain significance (Jan 12, 2018)910525
7-65960803-T-C Mucopolysaccharidosis type 7 Uncertain significance (Jan 13, 2018)910526
7-65960842-G-A Mucopolysaccharidosis type 7 Benign (Jan 12, 2018)360548
7-65960874-C-A Likely benign (Oct 26, 2017)558970
7-65960885-T-C Mucopolysaccharidosis type 7 Uncertain significance (Jan 13, 2018)910527
7-65960906-CA-TG Mucopolysaccharidosis type 7 Likely benign (Jan 19, 2024)2742036
7-65960907-A-G not specified • Mucopolysaccharidosis type 7 Benign (Feb 01, 2024)92588
7-65960908-G-A Mucopolysaccharidosis type 7 Likely benign (May 05, 2022)2073568
7-65960911-T-G Mucopolysaccharidosis type 7 Uncertain significance (Aug 24, 2021)660494
7-65960924-T-C Mucopolysaccharidosis type 7 • GUSB-related disorder Likely benign (Jan 19, 2024)1077388
7-65960926-G-A Mucopolysaccharidosis type 7 Uncertain significance (May 13, 2022)1962283
7-65960927-T-C Mucopolysaccharidosis type 7 Likely benign (Jul 10, 2023)2737618
7-65960934-G-GCTA Mucopolysaccharidosis type 7 • GUSB-related disorder Likely benign (Jan 16, 2024)590834
7-65960941-A-G Mucopolysaccharidosis type 7 Uncertain significance (Jan 13, 2018)911767
7-65960942-G-A Mucopolysaccharidosis type 7 Likely benign (Jun 27, 2023)2995084
7-65960948-A-G Mucopolysaccharidosis type 7 Likely benign (Mar 04, 2022)2104283
7-65960952-C-G Inborn genetic diseases Uncertain significance (Feb 11, 2022)2206855
7-65960957-T-C Mucopolysaccharidosis type 7 Likely benign (Jan 01, 2024)2727904
7-65960966-A-C Mucopolysaccharidosis type 7 Uncertain significance (Feb 03, 2022)1051643
7-65960967-A-G Mucopolysaccharidosis type 7 Uncertain significance (Mar 13, 2022)2170077
7-65960966-A-AATC GUSB-related disorder Uncertain significance (Feb 15, 2024)2629265

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
GUSBprotein_codingprotein_codingENST00000304895 1221631
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
4.04e-80.99712564801001257480.000398
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense1.103153750.8400.00002394208
Missense in Polyphen104153.550.677321771
Synonymous-0.7981731601.080.00001101282
Loss of Function2.711835.40.5080.00000202358

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.001080.00106
Ashkenazi Jewish0.0003310.000298
East Asian0.0001140.000109
Finnish0.0002010.000185
European (Non-Finnish)0.0004810.000431
Middle Eastern0.0001140.000109
South Asian0.0004490.000425
Other0.0005740.000489

dbNSFP

Source: dbNSFP

Function
FUNCTION: Plays an important role in the degradation of dermatan and keratan sulfates.;
Disease
DISEASE: Mucopolysaccharidosis 7 (MPS7) [MIM:253220]: An autosomal recessive lysosomal storage disease characterized by inability to degrade glucuronic acid-containing glycosaminoglycans. The phenotype is highly variable, ranging from severe lethal hydrops fetalis to mild forms with survival into adulthood. Most patients with the intermediate phenotype show hepatomegaly, skeletal anomalies, coarse facies, and variable degrees of mental impairment. {ECO:0000269|PubMed:12522561, ECO:0000269|PubMed:12859417, ECO:0000269|PubMed:1702266, ECO:0000269|PubMed:7573038, ECO:0000269|PubMed:7633414, ECO:0000269|PubMed:7680524, ECO:0000269|PubMed:8089138, ECO:0000269|PubMed:8111412, ECO:0000269|PubMed:8111413, ECO:0000269|PubMed:8644704, ECO:0000269|PubMed:8707294, ECO:0000269|PubMed:9099834, ECO:0000269|PubMed:9490302}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
Lysosome - Homo sapiens (human);Drug metabolism - other enzymes - Homo sapiens (human);Porphyrin and chlorophyll metabolism - Homo sapiens (human);Pentose and glucuronate interconversions - Homo sapiens (human);Glycosaminoglycan degradation - Homo sapiens (human);Glycogen synthetase deficiency;Glycogenosis, Type III. Cori disease, Debrancher glycogenosis;Mucopolysaccharidosis VI. Sly syndrome;Sucrase-isomaltase deficiency;Glycogenosis, Type IV. Amylopectinosis, Anderson disease;Glycogenosis, Type VI. Hers disease;Hereditary Coproporphyria (HCP);Porphyria Variegata (PV);Congenital Erythropoietic Porphyria (CEP) or Gunther Disease;Acute Intermittent Porphyria;Starch and Sucrose Metabolism;Porphyrin Metabolism;Neutrophil degranulation;Hyaluronan uptake and degradation;Hyaluronan metabolism;Metabolism of carbohydrates;HS-GAG degradation;Heparan sulfate/heparin (HS-GAG) metabolism;Glycosaminoglycan metabolism;Innate Immune System;Immune System;Metabolism (Consensus)

Intolerance Scores

loftool
0.0891
rvis_EVS
-0.82
rvis_percentile_EVS
11.88

Haploinsufficiency Scores

pHI
0.173
hipred
Y
hipred_score
0.531
ghis
0.598

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.996

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Gusb
Phenotype
hematopoietic system phenotype; normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); reproductive system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); skeleton phenotype; renal/urinary system phenotype; limbs/digits/tail phenotype; hearing/vestibular/ear phenotype; craniofacial phenotype; growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); endocrine/exocrine gland phenotype; homeostasis/metabolism phenotype; cellular phenotype;

Gene ontology

Biological process
carbohydrate metabolic process;glycosaminoglycan catabolic process;glucuronoside catabolic process;hyaluronan catabolic process;neutrophil degranulation
Cellular component
extracellular region;extracellular space;membrane;azurophil granule lumen;lysosomal lumen;intracellular membrane-bounded organelle;extracellular exosome;ficolin-1-rich granule lumen
Molecular function
beta-glucuronidase activity;signaling receptor binding;protein domain specific binding;carbohydrate binding